In a finding that highlights ways to optimize the efficacy of antibody-based therapeutics and vaccines, the activity of potent HIV-1-neutralizing antibodies has been confirmed to depend on cellular binding to the antibodies' Fc regions.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Koff, W. C. et al. Science 340, 1232910 (2013).
Burton, D. R. et al. Cell Host Microbe 12, 396–407 (2012).
Mascola, J. R. & Montefiori, D. C. Annu. Rev. Immunol. 28, 413–444 (2010).
Bournazos, S. et al. Cell 158, 1243–1253 (2014).
Hessell, A. J. et al. Nature 449, 101–104 (2007).
Barouch, D. H. et al. Nature 503, 224–228 (2013).
Klein, F. et al. Nature 492, 118–122 (2012).
Trkola, A. et al. Nature Med. 11, 615–622 (2005).
Poignard, P. et al. Immunity 10, 431–438 (1999).
Ko, S.-Y. et al. Nature http://dx.doi.org/10.1038/nature13612 (2014).
Abela, I. A. et al. PLoS Pathog. 8, e1002634 (2012).
Ackerman, M. E., Dugast, A. S. & Alter, G. Annu. Rev. Med. 63, 113–130 (2012).
Ackerman, M. E. & Alter, G. Curr. HIV Res. 11, 365–377 (2013).
Huber, M. et al. PLoS Med. 3, e441 (2006).
Burton, D. R. et al. Proc. Natl Acad. Sci. USA 108, 11181–11186 (2011).
Platt, E. J., Gomes, M. M. & Kabat, D. Proc. Natl Acad. Sci. USA 109, 7829–7834 (2012).
Ruprecht, C. R. et al. J. Exp. Med. 208, 439–454 (2011).
Yasmeen, A. et al. Retrovirology 11, 41 (2014).
Magnus, C., Rusert, P., Bonhoeffer, S., Trkola, A. & Regoes, R. R. J. Virol. 83, 1523–1531 (2009).
Rights and permissions
About this article
Cite this article
Trkola, A. Potency needs constancy. Nature 514, 442–443 (2014). https://doi.org/10.1038/514442a